Author:
Dedonder Jonathan,Gelgon Christelle,Guerder Antoine,Nion Nathalie,Lavault Sophie,Morélot-Panzini Capucine,Gonzalez-Bermejo Jésus,Benoit Laelia,Similowski Thomas,Serresse Laure
Abstract
Abstract
Background
Dyspnea conveys an upsetting or distressing experience of breathing awareness. It heavily weighs on chronic respiratory disease patients, particularly when it persists despite maximal treatment of causative abnormalities. The physical, psychological and social impacts of persistent dyspnea are ill-appreciated by others. This invisibility constitutes a social barrier and impedes access to care. This study aimed to better understand dyspnea invisibility in patients with chronic obstructive pulmonary disease (COPD) through quantitative discourse analysis.
Methods
We conducted a lexicometric analysis (lemmatization, descending hierarchical classification, multicomponent analysis, similarity analysis) of 11 patients' discourses (6 men, severe COPD; immediate postexacerbation rehabilitation) to identify semantic classes and communities, which we then confronted with themes previously identified using interpretative phenomenological analysis (IPA).
Results
Class#1 ("experience and need for better understanding"; 38.9% of semantic forms, 50% of patients) illustrates the gap that patients perceive between their experience and what others see, confirming the importance of dyspnea invisibility in patients' concerns. Class#2 ("limitations"; 28.7% of forms) and Class#3 (management"; 13.1% of forms) point to the weight of daily limitations in performing basic activities, of the need to accept or adapt to the constraints of the disease. These three classes matched previously identified IPA-derived themes. Class#4 ("hospitalization"; 18.2% of forms) points to the importance of interactions with the hospital, especially during exacerbations, which constitutes novel information.
Conclusions
Lexicometry confirms the importance of dyspnea invisibility as a burden to COPD patients.
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–52.
2. Carel H, Macnaughton J, Dodd J. Invisible suffering: breathlessness in and beyond the clinic. Lancet Respir Med. 2015;3:278–9.
3. Carel H: Invisible suffering: the experience of breathlessness. In: Atmospheres of Breathing. Skof L, Berndtson P eds., Albany (NY); 2018: Wellcome Trust-Funded Monographs and Book Chapters].
4. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekstrom M, Similowski T, Currow DC. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017;49:1602277.
5. Morelot-Panzini C, Adler D, Aguilaniu B, Allard E, Bautin N, Beaumont M, Blanc FX, Chenivesse C, Dangers L, Delclaux C, et al. Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic. Eur Respir J. 2017;50:1701297.